DK0486526T3 - Bindingsligander for tumornekrosefaktor - Google Patents

Bindingsligander for tumornekrosefaktor

Info

Publication number
DK0486526T3
DK0486526T3 DK90911467.0T DK90911467T DK0486526T3 DK 0486526 T3 DK0486526 T3 DK 0486526T3 DK 90911467 T DK90911467 T DK 90911467T DK 0486526 T3 DK0486526 T3 DK 0486526T3
Authority
DK
Denmark
Prior art keywords
necrosis factor
tumor necrosis
binding ligands
ligands
binding
Prior art date
Application number
DK90911467.0T
Other languages
Danish (da)
English (en)
Inventor
Deborah Anne Rathjen
Roger Aston
Original Assignee
Peptide Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25643730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0486526(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Peptide Technology Ltd filed Critical Peptide Technology Ltd
Application granted granted Critical
Publication of DK0486526T3 publication Critical patent/DK0486526T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK90911467.0T 1989-08-07 1990-08-07 Bindingsligander for tumornekrosefaktor DK0486526T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPJ566289 1989-08-07
AUPJ757689 1989-11-24

Publications (1)

Publication Number Publication Date
DK0486526T3 true DK0486526T3 (da) 1996-06-24

Family

ID=25643730

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90911467.0T DK0486526T3 (da) 1989-08-07 1990-08-07 Bindingsligander for tumornekrosefaktor

Country Status (8)

Country Link
US (2) US7605233B2 (fr)
EP (1) EP0486526B2 (fr)
JP (7) JP3443119B2 (fr)
AU (1) AU640400B2 (fr)
CA (1) CA2064915C (fr)
DE (2) DE10399036I1 (fr)
DK (1) DK0486526T3 (fr)
WO (1) WO1991002078A1 (fr)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0486526B2 (fr) 1989-08-07 2001-03-07 Peptech Limited Ligands de liaison du facteur de necrose de tumeurs
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US5959087A (en) 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
US6451983B2 (en) 1989-08-07 2002-09-17 Peptech Limited Tumor necrosis factor antibodies
EP0487610B1 (fr) * 1989-08-16 2000-02-09 Chiron Corporation Anticorps prohormone pour blocage du site de clivage
EP1132471A3 (fr) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag Protéines liant le TNF
CA2078000C (fr) * 1990-03-12 2001-10-02 Deborah A. Rathjen Peptides stimulateurs de neutrophile
US5587457A (en) * 1990-03-12 1996-12-24 Peptide Technology Limited Neutrophil stimulating peptides
US6375928B1 (en) 1990-03-12 2002-04-23 Peptech Limited Neutrophil stimulating peptides
EP0521918A4 (en) * 1990-03-19 1993-05-05 Peptide Technology Ltd Anti-tumour peptides
DE69132470D1 (de) * 1990-08-06 2000-12-21 Chiron Corp Verfahren zum nachweis von cytokinkonvertasehemmern
AU654501B2 (en) * 1990-08-27 1994-11-10 Peptide Technology Ltd. Method of treating viral infection
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
DE07012626T1 (de) * 1991-03-18 2010-01-21 New York University Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
EP0593585B1 (fr) * 1991-07-05 2002-05-02 Peptech Limited Peptide neutralisant la toxicite du facteur de necrose tumorale alpha (fnt) et la toxicite des lipopolysaccharides (lps)
JPH06510122A (ja) * 1991-08-23 1994-11-10 エヌチップ　インコーポレイテッド パッケージされていない集積回路のバーン・イン技術
GB2260902A (en) * 1991-09-12 1993-05-05 Eurocetus Bv Interleukin-2 and tumour necrosis factor for treating bladder cancer
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
ATE270111T1 (de) * 1993-03-18 2004-07-15 Cytimmune Sciences Inc Zusammensetzung und methode zur reduktion der toxizität von biologisch-aktiven faktoren
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
FI955798A7 (fi) * 1993-06-03 1996-02-01 Therapeutic Antibodies Inc Terapeuttiset vasta-ainefrangmentit
US5958409A (en) * 1993-07-30 1999-09-28 Kennedy Institute Of Rheumatology Method for treating multiple sclerosis
US20010055581A1 (en) 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
CA2218522A1 (fr) * 1995-04-20 1996-10-24 The Kennedy Institute Of Rheumatology Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf)
US7427492B1 (en) 1995-06-05 2008-09-23 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor receptor-like2
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE122004000003I2 (de) 1996-02-09 2007-03-29 Abbott Biotech Ltd Humane Antikörper welche an humanen TNFalpha Binden
US7229841B2 (en) 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US6407218B1 (en) 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
CA2365405A1 (fr) * 1999-03-22 2000-09-28 Human Genome Sciences, Inc. Recepteur tr2 du facteur de necrose tumorale chez l'homme
US6579522B1 (en) * 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
CA2817619A1 (fr) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methodes pour administrer des anticorps anti-tnf.alpha.
WO2004003019A2 (fr) * 2002-06-28 2004-01-08 Domantis Limited Ligand
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
CA2490409A1 (fr) 2002-06-28 2004-01-08 Centocor, Inc. Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP2267032A3 (fr) 2002-11-08 2011-11-09 Ablynx N.V. Procédé d'administration de polypeptides thérapeutiques et polypeptides correspondants
ES2551682T3 (es) * 2002-11-08 2015-11-23 Ablynx N.V. Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
JP2006520584A (ja) * 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
RU2357974C2 (ru) * 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
US7344716B2 (en) 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US7553827B2 (en) 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
JP2007502327A (ja) 2003-05-13 2007-02-08 デピュイ スパイン、インコーポレイテッド 椎間板変性症の治療法
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
US8361467B2 (en) 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
UA89481C2 (uk) 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
JP2008504216A (ja) 2003-12-02 2008-02-14 サイトイミューン サイエンシズ インコーポレイテッド モノクローナル抗体の生成のための方法および組成物
ES2388435T3 (es) * 2003-12-10 2012-10-15 Medarex, Inc. Anticuerpos de IP-10 y sus usos
MXPA06009805A (es) 2004-02-27 2007-04-02 Vaxconsulting Peptidos de interleucina 1 beta y factor de necrosis tumoral alfa y metodo de tratamiento utilizando los mismos.
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
MX2007014440A (es) 2005-05-16 2008-02-11 Abbott Biotech Ltd Uso de inhibidor de tnf para tratamiento de poliartritis erosiva.
ES2379283T3 (es) 2005-05-18 2012-04-24 Ablynx N.V. Proteínas de unión a albúmina sérica
SI1896073T1 (sl) 2005-06-30 2013-06-28 Janssen Biotech, Inc. Protitelesa proti il-23, sestavki, prostopki in uporabe
EP2548577B1 (fr) 2005-12-29 2017-02-15 Janssen Biotech, Inc. Anticorps humains anti-il-23, compositions, procédés et utilisations
WO2007087673A1 (fr) * 2006-02-01 2007-08-09 Arana Therapeutics Limited Produit d'assemblage d'anticorps à domaines
EP2004689A4 (fr) 2006-04-05 2010-06-02 Abbott Biotech Ltd Purification d'anticorps
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2007426A4 (fr) 2006-04-10 2010-06-16 Abbott Biotech Ltd Compositions destinées au traitement de la polyarthrite psoriasique et leurs applications
EP2010214A4 (fr) 2006-04-10 2010-06-16 Abbott Biotech Ltd Utilisations et compositions pour le traitement de la polyarthrite rhumatoïde
EP2043603A4 (fr) 2006-07-11 2010-10-27 Arubor Corp Prévention de la rhinosinusite et thérapie avec des inhibiteurs de cytokine proinflammatoires
SI2068889T1 (sl) 2006-08-10 2020-03-31 Roy C. Levitt Anakinra za uporabo pri zdravljenju sindroma bronchiolitisa obliteransa
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
MX2009012492A (es) 2007-05-21 2010-01-20 Alder Biopharmaceuticals Inc Anticuerpos para il-6 y sus usos.
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
WO2008144753A2 (fr) * 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Anticorps anti-tnf alpha et leur utilisation
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
GB2453589A (en) 2007-10-12 2009-04-15 King S College London Protease inhibition
WO2009062151A1 (fr) 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions et procédés de production d'anticorps
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
SG10201604258YA (en) 2007-11-30 2016-07-28 Abbvie Biotechnology Ltd Anti-tnf antibody formulations
US8986696B2 (en) 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
BRPI0907186A2 (pt) 2008-01-15 2015-07-14 Abbott Gmbh & Co Kg Composições proteicas pulverizadas e métodos para sua produção
BR122018013284B1 (pt) 2008-10-29 2022-03-03 Ablynx N.V Formulações de moléculas de ligação ao antígeno de domínio único, seu método de formulação e seu uso, kit ou artigo de fabricação, bem como método para preparar uma formulação reconstituída contendo uma molécula de sdab
KR20110079693A (ko) 2008-10-29 2011-07-07 와이어쓰 엘엘씨 단일 도메인 항원 결합 분자의 정제 방법
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
EP2467404B1 (fr) 2009-08-20 2015-09-30 Biosceptre International Limited Anticorps anti-récepteur p2x7 et fragments de ceux-ci
JP5934652B2 (ja) 2009-11-24 2016-06-15 アルダーバイオ ホールディングス エルエルシー Ｉｌ−６に対する抗体およびその使用
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
TWI538918B (zh) 2010-10-20 2016-06-21 財團法人工業技術研究院 人源化之單株抗體、其核苷酸序列與其用途
ES2601202T3 (es) 2010-11-11 2017-02-14 Abbvie Biotechnology Ltd Formulaciones liquidas de anticuerpos anti-TNT-alfa de alta concentración
WO2012071554A2 (fr) 2010-11-23 2012-05-31 Alder Biopharmaceuticals, Inc. Anticorps anti-il-6 utilisés pour le traitement de la stomatite
EP2702077A2 (fr) 2011-04-27 2014-03-05 AbbVie Inc. Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
US9155784B2 (en) 2011-06-20 2015-10-13 Icahn School Of Medicine At Mount Sinai Anti-TNF-α therapy for the mucopolysaccharidoses and other lysosomal disorders
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014143205A1 (fr) 2013-03-12 2014-09-18 Abbvie Inc. Anticorps humains qui se lient au tnf-alpha et leurs procédés de préparation
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
PL2970980T3 (pl) 2013-03-15 2019-01-31 Janssen Biotech, Inc Sposoby wytwarzania kontrolujące zawartość C-końcowej lizyny, galaktozy i kwasu sjalowego w rekombinowanych białkach
WO2015051293A2 (fr) 2013-10-04 2015-04-09 Abbvie, Inc. Utilisation d'ions métalliques pour moduler les profils de glycosylation des protéines dans le cas de protéines recombinées
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
HK1250040A1 (zh) 2015-03-31 2018-11-23 Sorriso Pharmaceuticals, Inc. 多肽
KR102789821B1 (ko) 2015-03-31 2025-04-02 소리소 파마슈티컬스 인크. 프로테아제-절단가능 링커를 갖는 펩티드 구조물
EA035638B1 (ru) 2015-03-31 2020-07-20 ВиЭйчСКВЕАРД ЛИМИТЕД Полипептиды
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
EP3519438A1 (fr) 2016-09-30 2019-08-07 VHsquared Limited Compositions
EP3573658A4 (fr) 2017-01-30 2021-07-21 Janssen Biotech, Inc. Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
CN110418652A (zh) 2017-02-07 2019-11-05 詹森生物科技公司 用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法
CN113574066A (zh) 2019-01-15 2021-10-29 詹森生物科技公司 用于治疗幼年特发性关节炎的抗tnf抗体组合物和方法
KR20210118878A (ko) 2019-01-23 2021-10-01 얀센 바이오테크 인코포레이티드 건선성 관절염의 치료 방법에 사용하기 위한 항-tnf 항체 조성물
EP3938390A1 (fr) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
JP7662529B2 (ja) 2019-03-14 2025-04-15 ヤンセン バイオテツク，インコーポレーテツド 抗ｔｎｆ抗体組成物を産生するための方法
EP3938391A1 (fr) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Procédés de production de compositions d'anticorps anti-tnf
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
MX2021014882A (es) 2019-06-03 2022-03-25 Janssen Biotech Inc Anticuerpos anti-tnf, composiciones y métodos para el tratamiento de la espondilitis anquilosante activa.
CN113939531A (zh) 2019-06-03 2022-01-14 詹森生物科技公司 用于治疗银屑病关节炎的抗tnf抗体组合物和方法
JP7692844B2 (ja) 2019-06-21 2025-06-16 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
CA3144200A1 (fr) 2019-06-21 2020-12-24 Sorriso Pharmaceuticals, Inc. Compositions
EP3986931A1 (fr) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
WO2021028752A1 (fr) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anticorps anti-tfn pour le traitement du diabète de type i
EP4153220A4 (fr) 2020-05-21 2024-09-11 Janssen Biotech, Inc. Méthode de traitement d'une maladie intestinale inflammatoire au moyen d'une polythérapie d'anticorps dirigés contre il -23 et tnf alpha
IL309996A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-TNF antibody compositions
IL309997A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-TNF antibody compositions
EP4624487A1 (fr) * 2022-11-24 2025-10-01 Tokushima University Production d'anticorps dirigés contre une protéine

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983000930A1 (fr) 1981-09-08 1983-03-17 Univ Rockefeller Suppression de lipase de lipoproteine par un mediateur induit par l'endotoxine (analyse par choc)
US6419927B1 (en) 1981-09-08 2002-07-16 Anthony Cerami Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages
US4603106A (en) 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US5700466A (en) 1981-09-08 1997-12-23 The Rockefeller University Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor
US4822776A (en) 1981-09-08 1989-04-18 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US6309640B1 (en) 1981-09-08 2001-10-30 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
JPH07119760B2 (ja) 1984-07-24 1995-12-20 コモンウエルス・セ−ラム・ラボラトリ−ズ・コミッション ミモトープを検出または決定する方法
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
IL73883A (en) 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
DE3650150T2 (de) 1985-08-16 1995-04-27 The Rockefeller University, New York, N.Y. Modulator der anabolischen Aktivität und seine Verwendungen.
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
WO1987003489A1 (fr) 1985-12-05 1987-06-18 Biogen N.V. Combinaisons de facteurs de necrose tumorale et d'antibiotiques, et procedes de traitement des tumeurs
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4863727A (en) 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
JPS6393799A (ja) 1986-10-08 1988-04-25 Teijin Ltd 新規生理活性ポリペプチド
EP0287633B1 (fr) 1986-10-16 1993-07-07 The President And Fellows Of Harvard College Combinaisons de facteurs de necroses de tumeurs et d'agents anti-inflammatoires pour le traitement de maladies malignes et non malignes
US5782792A (en) 1986-11-21 1998-07-21 Cypress Bioscience, Inc. Method for treatment of rheumatoid arthritis
DE3888224T2 (de) * 1987-04-24 1994-07-21 Teijin Ltd Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung.
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
AU625613B2 (en) 1988-01-05 1992-07-16 Novartis Ag Novel chimeric antibodies
GB8805792D0 (en) 1988-03-11 1988-04-13 Celltech Ltd Medicaments
US5183657A (en) 1988-03-11 1993-02-02 Celltech Limited Antibodies for use in antilymphocyte antibody therapy
GB8806339D0 (en) 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
US5215743A (en) 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
JPH01268645A (ja) 1988-04-18 1989-10-26 Teijin Ltd シュワルツマン反応抑制剤
DE3823804A1 (de) 1988-07-14 1990-01-18 Basf Ag Neutralisation der in vitro und in vivo toxischen eigenschaften von tnf-(alpha) durch monoklonale antikoerper und den davon abgeleiteten fragmenten
WO1990000400A1 (fr) 1988-07-15 1990-01-25 The Trustees Of Columbia University In The City Of New York Facteurs ameliorateurs de necrose tumorale et procedes de preparation et d'utilisation de tels facteurs
WO1990000902A1 (fr) 1988-07-18 1990-02-08 Chiron Corporation Anticorps monoclonaux reagissant avec la cachetine
EP0355067A1 (fr) 1988-08-19 1990-02-21 Celltech Limited Produits pharmaceutiques utiles dans le traitement des néoplasmes
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
US5360716A (en) 1988-10-24 1994-11-01 Otsuka Pharmaceutical Co., Ltd. Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α
JPH02227095A (ja) 1988-10-24 1990-09-10 Otsuka Pharmaceut Co Ltd モノクローナル抗体
EP0366043B1 (fr) * 1988-10-24 1994-03-30 Otsuka Pharmaceutical Co., Ltd. Anticorps monoclonal
US5223395A (en) 1988-12-01 1993-06-29 Centocor, Inc. Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples
US5342613A (en) 1988-12-27 1994-08-30 Health Research Inc. Pharmaceutical compositions and use thereof in the treatment of psoriasis
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
PT92900A (pt) 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
US5539084A (en) 1989-02-17 1996-07-23 Coselco Mimotopes Pty. Ltd. Method for the use and synthesis of peptides
EP0393438B1 (fr) 1989-04-21 2005-02-16 Amgen Inc. Récepteur du TNF, protéine liant le TNF at ADN codant pour ceux-ci
DK0398327T4 (da) 1989-05-18 2013-04-15 Yeda Res & Dev Tumornekrosefaktor-bindende protein, dets oprensning og antistoffer dertil
US6451983B2 (en) 1989-08-07 2002-09-17 Peptech Limited Tumor necrosis factor antibodies
US5644034A (en) 1989-08-07 1997-07-01 Peptide Technology Ltd. Tumour necrosis factor binding ligands
EP0486526B2 (fr) * 1989-08-07 2001-03-07 Peptech Limited Ligands de liaison du facteur de necrose de tumeurs
US5959087A (en) 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
EP1132471A3 (fr) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag Protéines liant le TNF
GB8921123D0 (en) 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
EP0433900B1 (fr) 1989-12-13 1995-09-20 Yeda Research And Development Company Limited Expression de la protéine de liaison I au facteur de nécrose tumorale TBP-I recombinante
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE4037604A1 (de) 1990-04-25 1991-10-31 Bayer Ag Verwendung von anti-tnf-antikoerpern als arzneimittel bei der behandlung von ischaemien und deren folgen
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9015908D0 (en) 1990-07-19 1990-09-05 Celltech Ltd Multivalent immunoglobulin
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
US5958413A (en) 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
US5994510A (en) 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB9028123D0 (en) 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
ES2145744T5 (es) 1991-01-18 2008-02-01 Amgen Inc. Procedimientos para tratar las enfermedades inducidas por el factor de necrosis tumoral.
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
DE07012626T1 (de) 1991-03-18 2010-01-21 New York University Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
EP0605442B1 (fr) 1991-07-25 2003-04-16 Idec Pharmaceuticals Corporation Anticorps de recombinaison pour therapie humaine
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
WO1993006213A1 (fr) 1991-09-23 1993-04-01 Medical Research Council Production d'anticorps chimeriques - une approche combinatoire
US20010021513A1 (en) 1991-11-21 2001-09-13 Puijk Wouter Cornelis Test device comprising a plate containing a multiplicity of wells with an associated metering device, as well as a kit which comprises these devices and use of the devices
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
DE4202665A1 (de) 1992-01-28 1993-07-29 Schering Ag Prostacyclin- und carbacyclinderivate als mittel zur behandlung von multipler sklerose
US5237024A (en) 1992-06-11 1993-08-17 Monsanto Company Preparing monoalkenyl aromatic monomer-maleic half ester copolymer
ATE172880T1 (de) 1992-08-28 1998-11-15 Bayer Ag Verwendung von monoklonalen anti-tnf-antikörpern für die behandlung von bakteriellen meningitiden
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
AU5152293A (en) 1992-10-08 1994-05-09 Kennedy Institute Of Rheumatology, The Treatment of autoimmune and inflammatory disorders
EP0671936A1 (fr) 1992-10-15 1995-09-20 Dana-Farber Cancer Institute, Inc. TRAITEMENT DE LA RESISTANCE A L'INSULINE DANS LE DIABETE DE TYPE II LIE A L'OBESITE, AU MOYEN D'ANTAGONISTES DE LA FONCTION DU FACTEUR -$g(a) DE NECROSE TUMORALE
GB9225448D0 (en) 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
PT614984E (pt) 1993-03-05 2001-12-28 Bayer Ag Anticorpos humanos anti-tnf
SE9302490D0 (sv) 1993-07-26 1993-07-26 Kabi Pharmacia Ab New use of old drugs
US5775947A (en) * 1993-07-27 1998-07-07 Japan Aviation Electronics Industry, Limited Multi-contact connector with cross-talk blocking elements between signal contacts
GB9403909D0 (en) 1994-03-01 1994-04-20 Erba Carlo Spa Ureido derivatives of naphthalenephosphonic acids and process for their preparation
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
FR2728793A1 (fr) 1994-12-28 1996-07-05 Oreal Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
US5872210A (en) 1995-10-05 1999-02-16 The United States Of America As Represented By The Department Of Health And Human Services Transframe peptide inhibitor of viral protease
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE122004000003I2 (de) 1996-02-09 2007-03-29 Abbott Biotech Ltd Humane Antikörper welche an humanen TNFalpha Binden
GB9702088D0 (en) 1997-01-31 1997-03-19 Pharmacia & Upjohn Spa Matrix metalloproteinase inhibitors
US5885800A (en) 1997-02-04 1999-03-23 Smithkline Beecham Corporation DNA encoding tumor necrosis related receptor, TR4
CA2221687A1 (fr) 1997-02-05 1998-08-05 Smithkline Beecham Corporation Recepteurs relies a la necrose des tumeurs, tr5
US20010010924A1 (en) 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
EP0869179A1 (fr) 1997-04-02 1998-10-07 Smithkline Beecham Corporation Récepteur en rapport avec la nécrose des tumeurs, TR7
CA2290021A1 (fr) 1997-05-12 1998-11-19 The Kennedy Institute Of Rheumatology Suppression therapeutique du facteur de necrose tumorale alpha et du facteur de croissance des cellules endotheliales vasculaires
US6472367B1 (en) 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
IL143045A0 (en) 1998-11-13 2002-04-21 Pepscan Systems Bv A method for determining a mimotope sequence
US6982089B2 (en) 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
US6419944B2 (en) 1999-02-24 2002-07-16 Edward L. Tobinick Cytokine antagonists for the treatment of localized disorders
WO2000062790A2 (fr) 1999-04-19 2000-10-26 Immunex Corporation Traitement de troubles d'ordre medical par un recepteur de facteur de necrose tumorale soluble
EP1125905A1 (fr) 2000-02-16 2001-08-22 Pepscan Systems B.V. Synthèse de segments
EP1197755A1 (fr) 2000-10-11 2002-04-17 Pepscan Systems B.V. Identification de sites de liaison de protéines
WO2002066984A2 (fr) 2001-02-16 2002-08-29 Pepscan Systems B.V. Reseaux de pixels
EP1279962A1 (fr) 2001-07-27 2003-01-29 Pepscan Systems B.V. Peptides synthétiques qui miment les épitopes conformationnelles de TNF-alpha
US20040014227A1 (en) 2002-01-04 2004-01-22 Frederick Erik D. Apparatus, method and computer program product for automated high-throughput sampling and data acquisition
US6564407B1 (en) * 2002-02-09 2003-05-20 Tom Tho-Truong Luu Travel pillow for accomodating the thighs of a seated user
WO2004042019A2 (fr) 2002-10-30 2004-05-21 Pointilliste, Inc. Systemes d'interception et d'analyse de particules biologiques et procedes d'utilisation de ceux-ci
EP1452868A2 (fr) 2003-02-27 2004-09-01 Pepscan Systems B.V. Procédé pour sélectionner un médicament d'intérêt potentiel

Also Published As

Publication number Publication date
EP0486526B2 (fr) 2001-03-07
US7605233B2 (en) 2009-10-20
JP4469013B2 (ja) 2010-05-26
EP0486526B1 (fr) 1996-05-22
JP2008174559A (ja) 2008-07-31
DE10399036I1 (de) 2004-04-01
JP2006089503A (ja) 2006-04-06
WO1991002078A1 (fr) 1991-02-21
JP2003231699A (ja) 2003-08-19
JP2007197458A (ja) 2007-08-09
US20100125130A1 (en) 2010-05-20
CA2064915C (fr) 2001-05-29
JP3977395B2 (ja) 2007-09-19
JP3443119B2 (ja) 2003-09-02
DE69027121T3 (de) 2001-08-30
DE69027121T2 (de) 1996-11-14
EP0486526A1 (fr) 1992-05-27
US20080234469A1 (en) 2008-09-25
JP2009114218A (ja) 2009-05-28
JPH04507195A (ja) 1992-12-17
DE69027121D1 (de) 1996-06-27
AU6145490A (en) 1991-03-11
CA2064915A1 (fr) 1991-02-08
EP0486526A4 (en) 1993-05-05
JP2003096096A (ja) 2003-04-03
JP3717466B2 (ja) 2005-11-16
AU640400B2 (en) 1993-08-26

Similar Documents

Publication Publication Date Title
DK0486526T3 (da) Bindingsligander for tumornekrosefaktor
FI895346A7 (fi) Sitoutuvia proteiineja
FI921116L (fi) Suodatinsektori
DE68918918D1 (de) Mikrowellenfilter.
FI910973A7 (fi) Tuumorinekroositekijäreseptorin vasta-aine
IT8967157A0 (it) Macchina binatrice
FI862531A7 (fi) Kasvainnekroositekijä.
DE69008470D1 (de) Loseblatt-Binder.
NO170057C (no) Skibinding for langrennsski.
KR930702896A (ko) 종양괴사인자 억제제
FI922220A7 (fi) Spesifiset sitoutumisaineet
BR9004713A (pt) Grampeador
KR900008652A (ko) 땜납 결합재
ATA39689A (de) Skibindung
ZA903843B (en) Tumor necrosis factor binding protein ii,its purification and antibodies thereto
NO894247L (no) Skibinding for langrennski.
KR910008389U (ko) 원예용 결속기
ATA22289A (de) Skibindung
KR900008248U (ko) 제본용 지철구
ATA900789A (de) 2-komponenten-bindemittel
FI912070A7 (fi) Magneettinen suodatin
KR910004175U (ko) 앨범대지
DE59001268D1 (de) Mikrowellen filter.
KR910008349U (ko) 결속용 밴드
KR910001625U (ko) 전선 결속용 콘넥터